Organization | Stallergenes

Stallergenes Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3

Founded: Antony Hauts-de-Seine France (1962)

Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial

2002

NCT00410930

First Marketed Drug

2013

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair)

First NDA Approval

2013

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair)

Last Known Activity

2015

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair) (2013 NDA)

Drugs in Phase 3 Trials (5)

Key: Stallergenes (4) Acquired (1)

birch pollen allergen extract (2 trials)

house dust mite allergen (6 trials)

short ragweed pollen allergen (4 trials)

staloral (1 trial)

timothy grass pollen allergen extract (Grastek) (7 trials)

Drugs in Phase 2 Trials (2)

Key: Stallergenes (1) Acquired (1)

milk powder (1 trial)

rbet v1-fv (3 trials)

Drugs in Phase 1 Trials (1)

Key: Stallergenes (0) Acquired (1)

pf-04236921 (1 trial)

Drugs in Other Trials (1)

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Asthma (Phase 2)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Hypersensitivity (Phase 3)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 3)

Stress, Psychological (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 25
# of Trial APIs: 9